SavedAdd your journal

Journals / Glokom Katarakt / 2010 / Cilt: 5 - Sayı: 1

Effectiveness of latanoprost %0.005 and timolol maleat %0.5 fixed combination in patients with primary open-angle Glaucoma

Primer açık açılı Glokomlu hastalarda latanoprost %0.005 ve timolol maleat %0.5 sabit kombinasyonunun etkinliği

Didem ESEN
Mehmet ÜLKE
İbrahim Bülent BUTANRI
Mehmet Şahin SEVİM
Torun Banu ACAR
Suphi ACAR
Pages
34–37
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In patients with POAG LTFC is effective and safe treatment for reducing IOP.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the intraocular pressure (IOP) lowering effect, diurnal variation and adverse effects of Latanoprost %0.005 and Timolol Maleat %0.5 fixed combination (LTFC) in patients with Primary Open-Angle Glaucoma (POAG) Materials and Methods: In this prospective study,112 eyes of 56 patients with the diagnosis of POAG who haven’t received any glaucoma medication were included.
📊
Key Findings & Data:This group was treated with LTFC for 6 months.
💡
Conclusion & Impact:Conclusion: In patients with POAG LTFC is effective and safe treatment for reducing IOP.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the intraocular pressure (IOP) lowering effect, diurnal variation and adverse effects of Latanoprost %0.005 and Timolol Maleat %0.5 fixed combination (LTFC) in patients with Primary Open-Angle Glaucoma (POAG) Materials and Methods: In this prospective study,112 eyes of 56 patients with the diagnosis of POAG who haven&#8217;t received any glaucoma medication were included. This group was treated with LTFC for 6 months. Results: Pre and 6th month IOP was; 23.70±1.70 mmHg and 14.42±1.78 mmHg respectively. After 6 months of treatment the reduction of IOP was statistically significant. Compared with pre-treatment, at 3rd month diurnal variation was significantly lower (p<0.01). Systemic adverse effect was not observed in any patients. Mild and moderate conjunktival hyperemia was observed in 17 eyes, ocular irritation was observed in 20 eyes, ocular pain observed in 2 eyes, hypertrichosis observed in 8 eyes. Conclusion: In patients with POAG LTFC is effective and safe treatment for reducing IOP.

Özet

Amaç: Primer açık açılı glokom (PAAG) hastalarında Latanoprost %0.005 ve timolol maleat %0.5 sabit kombinasyonunun (LTSK) göz içi basıncı (GİB) üzerine etkisini, GİB’nda gün içinde meydana getirdiği dalgalanmayı, oküler ve sistemik yan etkilerini değerlendirmek. Gereç ve Yöntem: PAAG tanısı alarak ilk kez tedavi uygulanacak 56 hastanın 112 gözü prospektif olarak incelendi. Bu hasta grubuna 6 ay boyunca LTSK uygulandı. Bulgular: Başlangıç ve 6. ay GİB sırasıyla 23.70±1.70 mmHg ve 14.42±1.78 mmHg idi. 6. ayda GİB’nda istatistiksel olarak anlamlı bir düşüş görüldü. Başlangıç GİB’na göre 3. ayda gün içi dalgalanma düzeyinde anlamlı bir azalma saptandı (p<0.01). Hiçbir hastada sistemik yan etki görülmezken, 17 hastada hafif ve orta şiddete değişen konjonktiva hiperemisi 20 olguda oküler irritasyon, 2 olguda oküler ağrı ve 8 olguda kirpiklerde uzama saptandı. Sonuç: PAAG hastalarında LTSK göz içi basıncını etkili olarak düşürmede etkili ve güvenli bir ilaçtır.

🔖

Cite This Article

ESEN, D., ÜLKE, M., BUTANRI, İ. B., SEVİM, M. Ş., ACAR, T. B., ACAR, S. (2010). Effectiveness of latanoprost %0.005 and timolol maleat %0.5 fixed combination in patients with primary open-angle Glaucoma. Glokom Katarakt, Cilt: 5 - Sayı: 1, 34–37. https://ajindex.com/articles/226570

References (15)

  1. Quigley HA.: Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80:389-393
  2. American Academy of Ophthalmology, Basic and clinical science course, Glaucoma. 2000-2001;Chapter 2
  3. Brubaker RF.: Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am J Ophthalmol. 1996;121:473- 483
  4. Alm A, Stjernschantz J.: Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, eveningor morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102:1743-1752
  5. Watson P, Stjernschantz J.: A six-month, randomized, doublemasked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Studt Group. Ophthalmology. 1996;103:126-137
  6. Yalvaç I, Önol M.: Glokomlar. Aydın P, Akova YA. (eds): Temel Göz Hastalıkları. Güneş Kitapevi, Ankara, 2001;261-285
  7. Mao LK, Steward WC, Shields MB.: Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol. 1991;111:51-54
  8. The AGIS Investigators. Advenced Glaucoma Intervention Study(AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130:429-440
  9. Shin DH, Hughes BA, Song MS, et al.: Primary glaucoma triple procedure with or without adjunctive mitomycin. Prognostic factors for filtration faulire. Ophthalmology. 1996;103:1925-1933
  10. Patel SC, Spaeth GL.: Compliance in patients prescribed eyedrop for glaucoma. Ophthalmic Surg. 1995;26:233-236
  11. Weinreb RN.: Compliance with medical treatments of glaucoma. J Glaucoma. 1992;1:134-136
  12. Pfeiffer N.; European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its indivudial components. Graefes Arch Clin Exp Ophthalmol. 2002;204:893-899
  13. Hamacher T, Schinzel M, Schölzel-Klatt A, et al.: Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005 % / timolol maleate 0.5 % fixed combination from monotherapies and adjunctive therapies. Br J Ophthalmol. 2004;88: 1295-1298
  14. Konstas AG, Nakos E, Tersis I, et al.: A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol. 2002;133:753-757
  15. Higginbotham EJ, Feldman R, Stiles M, et al.: Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002;120:91